PFKFB3 and colorectal carcinoma: KAN0438757, the inhibitor of glycolysis-related gene PFKFB3, showed a significant anti-tumor effect in PDOs of CRC, but had no cytotoxicity in normal colonic organoids, indicating a promising therapeutical approach for CRC [88].